Seretra
✅ Reduces airway inflammation
✅ Improves lung function
✅ Relieves asthma symptoms
✅ Prevents bronchoconstriction
✅ Enhances respiratory health
Seretra contains Seratrodast.
✓ Medically reviewed by Morgan Ellis — Pharmacy Researcher · 8 years experience · Last reviewed: May 2026
⚡ Quick Answer — What is Seretra?
Seretra contains seratrodast 80 mg, a selective thromboxane A2 (TXA2) receptor antagonist used as preventer therapy for asthma and allergic rhinitis. Seratrodast blocks the TXA2 receptor on bronchial smooth muscle, eosinophils, and platelets — preventing TXA2-mediated bronchoconstriction, eosinophil recruitment, and airway hyperresponsiveness. It was developed and is mainly used in Japan; less widely available outside Asia. Used as add-on preventer alongside ICS in patients with persistent asthma. Onset of preventer benefit takes 1–2 weeks of daily dosing.
📦 Every order is covered by our Reshipment Assurance Policy — if your parcel does not arrive within 20 business days, we reship it.
Why order from MedsBase
Our generic medications are sourced from WHO-GMP certified manufacturers and shipped worldwide in discreet, plain packaging — no medication name on the parcel exterior. Card payments are routed through a regulated processor (statement descriptors include a regulated card-payment processor — never “MedsBase” or any medication name). Crypto and SEPA bank transfer are also accepted. Every order is backed by our Reshipment Assurance Policy.
What Is Seretra?
Seretra contains seratrodast — a niche anti-asthma agent introduced in Japan in 1995. Seratrodast targets the thromboxane A2 (TXA2) receptor — a contrast to leukotriene receptor antagonists (montelukast) which target the cysteinyl leukotriene receptor. Both TXA2 and leukotrienes are inflammatory mediators released during the allergic cascade.
How Does Seratrodast Work?
- TXA2 receptor blockade on bronchial smooth muscle prevents TXA2-mediated bronchoconstriction
- Reduces eosinophil recruitment to airways
- Decreases airway hyperresponsiveness over 1–2 weeks of dosing
- Mild platelet inhibition — TXA2 is a potent platelet aggregator; this effect is rarely clinically significant
Uses and Indications
- Persistent asthma — add-on preventer when ICS alone is inadequate
- Allergic rhinitis — adjunct
- Cough-variant asthma
- Aspirin-exacerbated respiratory disease (AERD) — niche use
Seretra Dosage
| Patient | Dose | Frequency |
|---|---|---|
| Adults | 80 mg | Once daily after dinner |
| Hepatic impairment | Reduce dose 50% | Once daily |
Side Effects of Seretra
- Nausea, dyspepsia
- Headache
- Mild dizziness
- Mild liver enzyme elevation
- Rarely: rash, fatigue
Serious — stop and seek help:
- Hepatitis (jaundice, dark urine, RUQ pain)
- Severe allergic reaction
- Severe persistent vomiting
Warnings and Precautions
- Liver function monitoring: baseline LFTs and periodic monitoring during long-term use.
- Continue ICS if previously prescribed; seratrodast is add-on, not replacement.
- Not a rescue medication. Use SABA (Asthalin, Levolin) for acute attacks.
- Pregnancy and breastfeeding: limited data; avoid unless benefit clear.
- Bleeding disorders: mild TXA2 inhibition could theoretically prolong bleeding; rarely clinically significant.
Contraindications
- Hypersensitivity to seratrodast
- Severe hepatic impairment
- Active hepatitis
Drug Interactions
- Aspirin and other antiplatelet agents — additive bleeding risk (rarely clinically significant)
- Warfarin — monitor INR
- Other hepatotoxic drugs — monitor LFTs
Storage
- Store below 25°C in a cool, dry place away from direct sunlight.
- Keep in original packaging until use to protect from moisture and light.
- Do not use after the expiry date printed on the strip.
- Keep out of reach of children.
Related Alternatives on MedsBase
- Asthalin Inhaler — salbutamol reliever
- Budecort Inhaler — budesonide ICS preventer
- Foracort Inhaler — budesonide + formoterol ICS-LABA
- Montair — montelukast LTRA tablet
- Tiova Inhaler — tiotropium LAMA for COPD
Frequently Asked Questions
How is seratrodast different from montelukast?
Both block specific allergic mediators. Montelukast (Montair) blocks the cysteinyl leukotriene CysLT1 receptor. Seratrodast blocks the thromboxane A2 receptor. Different mediators, different targets, similar add-on niche. Montelukast has more global use and a stronger evidence base; seratrodast is mainly used in Japan and parts of Asia.
Can I take Seretra alongside montelukast?
Combination is not standard. Discuss with your prescriber — there is no established additional benefit over ICS-LABA + LTRA.
How long until Seretra works?
1–2 weeks for noticeable improvement; 4–8 weeks for full preventer effect on exacerbation rate.
Is Seretra a rescue inhaler?
No — onset is far too slow. Use a SABA (Asthalin, Levolin) for acute attacks.
Why monitor liver function?
Mild liver enzyme elevation is a known side effect. Baseline LFTs and periodic monitoring are recommended.
Will Seretra replace my inhaler?
No — seratrodast is an oral add-on. Continue ICS or ICS-LABA inhaler therapy.
Is Seretra evidence-based?
Yes, but mainly through Japanese trials. Evidence base is smaller than for montelukast or ICS-LABA combinations. Reasonable as add-on in selected patients.
Can children take Seretra?
Limited paediatric data; specialist supervision required.
Is Seretra safe in pregnancy?
Limited data; avoid unless benefit clear.
Related Alternatives
Other products in Chronic Conditions that customers also view:
More options in Asthma/COPD Treatment
Ranked by recent MedsBase order volume — what other customers in this category are picking.
| Strength | 80 mg |
|---|---|
| Quantity | 30 Tablet/s, 60 Tablet/s, 90 Tablet/s, 180 Tablet/s |
Seretra
Q & A
Seretra
Related products
Reviews
There are no reviews yet